Fig 2. Differentiating human cell-based activities between two C15:0 compounds.

Clinically relevant biomarker activities that were different when comparing two C15:0 compounds (> 98% purity, 5.6 μM) acquired from different manufacturers (Product W433400 from Sigma Aldrich and FA15^TM from Seraphina Therapeutics). Different biomarker readouts were included when the readout for one compound was outside the significance envelope with an effect size > 20% (|log₁₀ ratio| > 0.1) in the same direction, and the other was not or was outside the significance envelope in the opposite direction.